Evaluation of Anxiety and Depression in Patients with Androgenetic Alopecia in Shanghai: A Cross-Sectional Study

Androgenetic alopecia (AGA) affects the quality of life (QoL) and has a negative psychological impact on patients. We sought to investigate the frequency of anxiety and depression in AGA patients and explore their relationship with patients’ QoL. This cross-sectional survey enrolled 192 participants with AGA. Hairdex, World Health Organization Quality of life Brief Version (WHOQOL-BREF), and dermatology life quality index (DLQI) instruments were used to assess the QoL of patients, and hospital anxiety and depression scale (HADS) was used to evaluate patients’ anxiety symptom and depression symptom. HADS, WHOQOL-BREF, and DLQI scores and domains of the Hairdex score were analyzed using linear regression and Pearson correlation. Apart from self-confidence, all four domains of Hairdex were significantly correlated with depression scores and anxiety scores. All four domains of WHOQOL-BREF were significantly correlated with depression and anxiety scores. While all six domains of DLQI were also significantly correlated with anxiety scores only. This study demonstrates a significant correlation between psychiatric morbidity and QoL in individuals with AGA. Hence, psychiatric treatment evaluations should be considered.

[1]  F. Khattab,et al.  Efficacy of botulinum toxin A injection in the treatment of androgenic alopecia: A Comparative Controlled Study , 2022, Journal of cosmetic dermatology.

[2]  M. Jafferany,et al.  Cross sectional quality of life assessment in patients with androgenetic alopecia , 2020, Dermatologic therapy.

[3]  G. Choi,et al.  Anxiety, depression, and stress in Korean patients with chronic urticaria , 2020, The Korean journal of internal medicine.

[4]  G. Girolomoni,et al.  The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  Isha Goyal,et al.  Quality of Life Assessment in Patients with Androgenetic Alopecia , 2019, International journal of trichology.

[6]  M. Mazzetti,et al.  HrQoL in hair loss‐affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  C. Fu,et al.  The dermatology life quality index (DLQI) and the hospital anxiety and depression (HADS) in Chinese rosacea patients , 2018, Psychology, health & medicine.

[8]  M. Noaman,et al.  Oxidative stress and psychiatric morbidity in patients with facial acne , 2018, Journal of cosmetic dermatology.

[9]  B. Piraccini,et al.  Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  M. Danyal,et al.  Impact of Androgenetic Alopecia on the Psychological Health of young men , 2018 .

[11]  Y. Mao,et al.  Analysis of quality of life and depression in patients with androgenetic alopecia or alopecia areata , 2017 .

[12]  A. Kouris,et al.  Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study* , 2016, Anais brasileiros de dermatologia.

[13]  S. Tee,et al.  A prospective cross‐sectional study of anxiety and depression in patients with psoriasis in Singapore , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  V. Topçuoğlu,et al.  Social Anxiety and Quality of Life in Vitiligo and Acne Patients with Facial Involvement: A Cross-Sectional Controlled Study , 2016, American Journal of Clinical Dermatology.

[15]  C. Papageorgiou,et al.  Quality of life and psychosocial impact of scarring and non‐scarring alopecia in women , 2015, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[16]  Y. Liu,et al.  Prevalence of androgenetic alopecia in China: a community‐based study in six cities , 2009, The British journal of dermatology.

[17]  Y. Sheng,et al.  Prevalence and types of androgenetic alopecia in Shanghai, China: a community‐based study , 2009, The British journal of dermatology.

[18]  P. Habibollahi,et al.  BMC Clinical Pharmacology BioMed Central Research article , 2006 .

[19]  R. Sinclair,et al.  The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen hair loss in women. , 2004, Journal of the American Academy of Dermatology.

[20]  P. Elsner,et al.  Hairdex Ein Instrument zur Untersuchung der krankheitsbezogenen Lebensqualität bei Patienten mit Haarerkrankungen , 2001, Der Hautarzt.

[21]  D L Patrick,et al.  Validation of the United States' version of the World Health Organization Quality of Life (WHOQOL) instrument. , 2000, Journal of clinical epidemiology.

[22]  M. Power,et al.  Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment , 1998, Psychological Medicine.

[23]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[24]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.

[25]  J. Hamilton PATTERNED LOSS OF HAIR IN MAN: TYPES AND INCIDENCE , 1951, Annals of the New York Academy of Sciences.